Larvol Delta - Phase-I-clinical-trial-to-evaluate-the-safety-and-immunogenicity-of-a-SARSCoV2-mRNA-vaccine-RBMRNA405-in-booster-immunization-in-people-aged-18-years-and-above

SARS-CoV-2 mRNA vaccine (RBMRNA) - Argorna Pharma

https://www.chictr.org.cn/showprojEN.html?proj=202641

Dec 5, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next